Alerts will be sent to your verified email
Verify Email
BIOCON
|
Biocon
|
Concord Biotech
|
Advanced Enzyme
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Pharmaceutical Sector
|
|||
|
Domestic Sales Growth - YoY
|
7.7 % | n/a | n/a |
|
Fermentation Capacity
|
125.0 KL | 1250.0 KL | n/a |
|
R&D as a % of Total Sales
|
7.0 % | 2.3 % | 10.41 % |
|
Financials
|
|||
|
5 yr Average ROE
|
5.97 % | 19.73 % | 10.77 % |
|
5yr average Equity Multiplier
|
2.64 | 1.21 | 1.15 |
|
5yr Average Asset Turnover Ratio
|
0.31 | 0.54 | 0.41 |
|
5yr Avg Net Profit Margin
|
7.2 % | 30.4 % | 22.63 % |
|
Price to Book
|
2.19 | 9.44 | 2.68 |
|
P/E
|
123.07 | 48.06 | 27.78 |
|
5yr Avg Cash Conversion Cycle
|
-193.26 Days | 76.63 Days | 109.31 Days |
|
Inventory Days
|
102.53 Days | 79.03 Days | 77.49 Days |
|
Days Receivable
|
139.43 Days | 132.49 Days | 61.31 Days |
|
Days Payable
|
307.82 Days | 157.9 Days | 49.86 Days |
|
5yr Average Interest Coverage Ratio
|
8.77 | 195.92 | 54.21 |
|
5yr Avg ROCE
|
6.71 % | 25.76 % | 14.52 % |
|
5yr Avg Operating Profit Margin
|
19.38 % | 43.43 % | 35.47 % |
|
5 yr average Debt to Equity
|
0.75 | 0.03 | 0.02 |
|
5yr CAGR Net Profit
|
6.47 % | 9.62 % | -2.12 % |
|
5yr Average Return on Assets
|
2.35 % | 16.36 % | 9.32 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
54.45 % | 44.08 % | 43.08 % |
|
Share Pledged by Promoters
|
0.0 | 0.0 | 0.0 |
|
Change in Promoter Holding (3 Yrs)
|
-6.19 % | 0.0 | -9.62 % |
|
Change in Mutual Fund Holding (3 Yrs)
|
12.19 % | -0.9 % | -0.59 % |
|
Biocon
|
Concord Biotech
|
Advanced Enzyme
|
|
|---|---|---|---|
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
|
Operating Profit Break-Up
|
Operating Profit Break-Up
|
-
|
-
|
|
Asset Break-Up
|
Asset Break-Up
|
Asset Break-Up
|
Asset Break-Up
|